David MacLean
@macleanoncology.bsky.social
Pancreatic Cancer researcher in Jen Morton's Lab at the CRUK Scotland Institute. Interested in the crosstalk between the tumour and its microenvironment in response to KRAS inhibition.
Previously a Research Assistant in Monica Olcina's Lab, Oxford.
Previously a Research Assistant in Monica Olcina's Lab, Oxford.
Reposted by David MacLean
We show this concept in efficacy studies using xenografts, orthotopic allografts, and KPC models in which the combo of RAS-MAPK and PIKfyve inhibitors resulted in regression/cures! Thanks especially to @jenmorton.bsky.social @macleanoncology.bsky.social @cruk-si.bsky.social @uofglasgow.bsky.social
April 24, 2025 at 3:20 PM
We show this concept in efficacy studies using xenografts, orthotopic allografts, and KPC models in which the combo of RAS-MAPK and PIKfyve inhibitors resulted in regression/cures! Thanks especially to @jenmorton.bsky.social @macleanoncology.bsky.social @cruk-si.bsky.social @uofglasgow.bsky.social
Reposted by David MacLean
Finally we heard from the winner of the inaugural Eric Aboagye Recognition Award - Prof Melissa B Davis!👏
Melissa's research focuses on identifying social, biological and environmental determinants of breast and prostate cancer outcomes in patients of African ancestry
Melissa's research focuses on identifying social, biological and environmental determinants of breast and prostate cancer outcomes in patients of African ancestry
February 26, 2025 at 5:05 PM
Finally we heard from the winner of the inaugural Eric Aboagye Recognition Award - Prof Melissa B Davis!👏
Melissa's research focuses on identifying social, biological and environmental determinants of breast and prostate cancer outcomes in patients of African ancestry
Melissa's research focuses on identifying social, biological and environmental determinants of breast and prostate cancer outcomes in patients of African ancestry